Agios Pharmaceuticals (AGIO) investor relations material

Strategic expansion and licensing agreement

• Entered an exclusive global license agreement for cevidoplenib, a next-generation oral SYK inhibitor, targeting immune thrombocytopenia (ITP), with Oscotec, including a $25 million upfront payment, up to $140 million in milestones, and tiered royalties; Oscotec retains option for exclusive rights in South Korea after Phase 3 results.

• Cevidoplenib aligns with a strategy to expand in rare hematology, leveraging existing expertise, commercial infrastructure, and overlapping prescriber base in hemolytic anemias.

• The deal structure is capital efficient, with most payments tied to development and regulatory milestones, and limited near-term OpEx impact.

• Commercial synergies expected due to significant overlap with current hematology/oncology prescriber base.

• The structure allows continued focus on 2026 priorities and pipeline launches.

Clinical rationale and differentiation

• Cevidoplenib is a highly selective SYK inhibitor designed for improved selectivity, pharmacokinetics, and durability, aiming for consistent exposure and durable response in chronic ITP.

• Phase II data showed dose-dependent activity, favorable safety, and sustained platelet control, especially at the 400 mg dose; 50% of patients on 400mg BID achieved ≥2 consecutive PLT ≥30,000/μL vs. 8.3% for placebo (p=0.015).

• Durable and clinically meaningful platelet responses were observed across multiple secondary endpoints, with no DLTs and a favorable safety profile, including limited GI events and lower rates of hypertension and neutropenia.

• Cevidoplenib demonstrated higher durability of response compared to other SYK and BTK inhibitors, with endpoints aligned to registrational standards.

• Received orphan drug designation from the FDA for ITP.

Development and financial outlook

• Phase III initiation planned for the first half of 2028, pending completion of CMC scale-up and process optimization.

• Upfront payment to Oscotec will be recognized as an R&D expense in Q2; operating expenses for 2026 expected to remain flat versus 2025, excluding the $25 million upfront payment.

• Expansion into ITP is expected to contribute to a rare disease portfolio targeting over $10 billion global market value by 2030.

• Cevidoplenib in ITP represents a potential $1 billion peak year sales opportunity in the U.S.

• No change to profitability trajectory or 2026 financial guidance.